Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Activated T regulatory (T reg) cells are potent suppressors that mediate immune tolerance. We investigated the relationship between activated T reg cells and the progression of human colon cancer. We designed a cross‐sectional study of CD4+Foxp3+ T cells from peripheral blood, primary tumor and nontumor colon tissue of 42 patients with colon cancer and correlated the percentages of different subgroups of T reg cells with colon cancer stage. The phenotypes, cytokine‐release patterns and suppression ability of these T reg cells were analyzed. We found that T reg cells increased significantly in both peripheral blood and cancer tissue. In addition, the T reg cells expressed significantly lower levels of CCR7, CD62L and CD45RA in comparison to normal volunteers. Further dividing T reg cells into subgroups based on Foxp3 and CD45RA expression revealed that both activated T reg cells (Foxp3 hi CD45RA−) and nonsuppressive T reg cells (Foxp3 lo CD45RA−), but not resting T reg cells (Foxp3 low CD45RA+), increased in the peripheral blood and cancer tissue of patients with colon cancer. Only the activated T reg cells expressed significantly higher levels of tumor necrosis factor receptor 2 and cytotoxic T‐cell antigen‐4. Activated T reg cells, however, secreted significantly lower levels of effector cytokines (interleukin‐2, tumor necrosis factor‐α and interferon‐γ) than did resting T reg cells and nonsuppressive cells upon ex vivo stimulation. Activated, but not resting, T reg cells in cancer tissue correlated with tumor metastases. In summary, we confirmed that activated T reg cells are a distinct subgroup with effector memory phenotype and fully functional regulatory activity against human colorectal cancer immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“CTLA-4 blockade could boost antitumor immune responses and is used in clinical therapy.(37) We therefore examined CTLA-4 expression in patients with CRC and found that it was also significantly increased only in the activated Treg cell population (Fig.”
BackgroundCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“CD4þ Foxp3þ Regulatory T cells (Treg cells) are essential to maintain self-tolerance and immune hemostasis.(1,2) They play important roles in a variety of human diseases including autoimmune disease, chronic infection and cancers.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · cited 1×
“Another major regulatory player is the CTLA-4 surface molecule.(35) Upregulation of CTLA-4 is associated with increased Treg cell number and activity in inflammatory bowel disease models.”
BackgroundAllan, S. E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bacchetta, R., Roncarolo, M. G., & Levings, M. K. (2007) · International Immunology · doi:10.1093/intimm/dxm014 · Cited by 872 · cited 1×
“postulated that activated CD4þ T cells might express Foxp3 but without regulatory activity.(20) CD4þFoxp3 T cells might transiently express lower levels of Key words: colorectal cancer, regulatory T cell, effector memory T”
Background
Cited by
Picard, E., Verschoor, C. P., Ma, G. W., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 522
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157
“CD4+CD45RA+Foxp3lo Treg cells as antigen-experienced cells are referred to as resting Treg cells (rTreg) [13–15].”
BackgroundRegulatory T‐cell heterogeneity and the cancer immune response
Ward‐Hartstonge, K. A., & Kemp, R. A. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.43 · Cited by 122
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
“These subtypes consist of suppressive cluster of differentiation (CD) 45RA+ forkhead-box-protein P3 (FOXP3) high naive-like cells, suppressive CD45RA–FOXP3-high effector Treg cells, and pro-inflammatory CD45RA–FOXP3-low effector Treg cells [22].”
BackgroundEpigenetic mechanisms of tumor resistance to immunotherapy
Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36
Metadata
- Authors
- Lin, Y., Mahalingam, J., Chiang, J., Su, P., Chu, Y., Lai, H., Fang, J., Huang, C., Chiu, C., & Lin, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-09-18
- Volume
- 132
- Issue
- 6
- Pages
- 1341-1350
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2049636267
- Cited by
- 112
- References
- 8
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.